Your browser doesn't support javascript.
loading
Efficacy and safety of the VASCADE® MVP venous vascular closure device in patients undergoing percutaneous left atrial appendage occlusion with WATCHMAN.
Golzarian, Hafez; Graebel, Katherine T; Bailey, Rachel; Widmer, Michael B; Thiel, Arielle; Hempfling, Gerri; Otto, Michael; Otto, Todd; Patel, Sandeep M.
Afiliação
  • Golzarian H; Internal Medicine Residency Program, Mercy Health-St. Rita's Medical Center, Lima, Ohio, USA.
  • Graebel KT; Department of Cardiovascular Disease, HCA Houston Healthcare - Kingwood/University of Houston College of Medicine, Houston, Texas, USA.
  • Bailey R; Internal Medicine Residency Program, Mercy Health-St. Rita's Medical Center, Lima, Ohio, USA.
  • Widmer MB; Internal Medicine Residency Program, Mercy Health-St. Rita's Medical Center, Lima, Ohio, USA.
  • Thiel A; Internal Medicine Residency Program, Mercy Health-St. Rita's Medical Center, Lima, Ohio, USA.
  • Hempfling G; Structural Heart & Intervention Center, Mercy Health-St. Rita's Medical Center, Lima, Ohio, USA.
  • Otto M; Structural Heart & Intervention Center, Mercy Health-St. Rita's Medical Center, Lima, Ohio, USA.
  • Otto T; Structural Heart & Intervention Center, Mercy Health-St. Rita's Medical Center, Lima, Ohio, USA.
  • Patel SM; Structural Heart & Intervention Center, Mercy Health-St. Rita's Medical Center, Lima, Ohio, USA.
Article em En | MEDLINE | ID: mdl-39279138
ABSTRACT

BACKGROUND:

The VASCADE MVP venous vascular closure system is commonly used for percutaneous venotomy closure in catheter-based procedures utilizing sheath sizes 6-12 French. However, its application with larger sheaths such as ones required in left atrial appendage occlusion (LAAO) has yet to be explored.

AIMS:

This study compared the efficacy and safety of VASCADE MVP versus conventional Figure-of-8 sutures (Fo8) for femoral venotomy closure in patients undergoing Watchman LAAO.

METHODS:

This single-center retrospective analysis included patients who underwent post-LAAO femoral venotomy closure with either VASCADE MVP or Fo8 sutures. The primary efficacy endpoint was time to hemostasis (TTH). Primary safety endpoints were 30-day access site-related readmissions and major complications. Minor access-site-related complications were also assessed.

RESULTS:

107 patients underwent post-LAAO femoral venotomy closure with VASCADE MVP, of which 101 were successful (94.4%). 99 patients underwent conventional closure with Fo8 sutures and supplemental manual pressure. Baseline characteristics were similar between groups. TTH was significantly shorter with VASCADE MVP (152.9 vs. 335.8 s, p = 0.001). Major safety outcomes were comparable. However, the conventional group experienced a higher incidence of ecchymosis (16.2% vs 4.7%, p = 0.007) and 30-day all-cause readmission (18.2% vs 8.4%, p = 0.038).

CONCLUSIONS:

VASCADE MVP significantly reduced TTH compared to Fo8 sutures after LAAO. While demonstrating a similar safety profile, VASCADE MVP may offer a more efficient approach to femoral vein closure in this patient population.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Catheter Cardiovasc Interv Assunto da revista: CARDIOLOGIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Catheter Cardiovasc Interv Assunto da revista: CARDIOLOGIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos